Quarterly ResultAug 6, 2026, 06:11 AM
Curaleaf Q2 Net Revenue $340M, Net Income $12M; US & Intl Growth
AI Summary
Curaleaf Holdings reported strong second-quarter 2026 financial results, with net revenue increasing 10% year-over-year to $340 million and net income reaching $12 million. The company saw significant growth in both its domestic and international segments, alongside a robust gross profit margin of 50%. Operational highlights include expanding its retail footprint, launching a new premium brand, and completing the buyout of its German subsidiary, Four20 Pharma.
Key Highlights
- Net revenue for Q2 2026 increased 10% year-over-year to $340.1 million.
- Net income from continuing operations was $12.5 million, or $0.05 per share.
- Gross profit margin stood at 50%, an increase of 70 basis points year-over-year.
- Adjusted EBITDA was $70.1 million, representing a 20.6% margin.
- Domestic revenue grew 7% year-over-year to $288.7 million.
- International revenue increased 26% year-over-year to $51.4 million.
- Completed buyout of remaining 45% equity in German subsidiary Four20 Pharma, achieving 100% ownership.
- Expanded retail footprint to 174 dispensaries nationwide, including 73 in Florida.
Price Impact
More from CURLF